View Item 

Show simple item record

NRC and FDA Regulations Affecting Nuclear Pharmacy Practice
dc.contributor.authorPetry, Neil A.en_US
dc.date.accessioned2010-04-14T14:20:33Z
dc.date.available2010-04-14T14:20:33Z
dc.date.issued1989en_US
dc.identifier.citationPetry, Neil (1989). "NRC and FDA Regulations Affecting Nuclear Pharmacy Practice." Journal of Pharmacy Practice 2(5): 306-313. <http://hdl.handle.net/2027.42/69138>en_US
dc.identifier.issn0897-1900en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/69138
dc.description.abstractRadiopharmaceuticals are radioactive drugs that are used in nuclear medicine practice for diagnosis and treatment of disease. Nuclear pharmacy practice is a patient-oriented pharmaceutical service that promotes the safe and efficacious use of radiopharmaceuticals and other drugs used in nuclear medicine, and is regulated jointly by a variety of federal, state, and local agencies. Given that the medical use of radiopharmaceuticals is highly regulated at multiple levels of government, it is not surprising that nuclear pharmacy practice is conducted in a complex regulatory environment. The purpose of this article is to provide a brief overview of this regulatory environment, primarily in terms of two important regulatory agencies involved (Nuclear Regulatory Commission and Food and Drug Administration), their primary authority and activities, and the regulations that must be satisfied in order to assure the safe and efficacious use of radiopharmaceuticals.en_US
dc.format.extent3108 bytes
dc.format.extent687249 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.titleNRC and FDA Regulations Affecting Nuclear Pharmacy Practiceen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity Hospital B1G412/ 0028, The University of Michigan Medical Center, 1500 E Medical Center Dr. Ann Arbor, MI 40109-0028en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/69138/2/10.1177_089719008900200509.pdf
dc.identifier.doi10.1177/089719008900200509en_US
dc.identifier.sourceJournal of Pharmacy Practiceen_US
dc.identifier.citedreferenceNuclear Pharmacy Practice Standards: American Pharmaceutical Association, Washington, DC, 1984en_US
dc.identifier.citedreferenceMeyers EL: Radiopharmaceuticals: Regulatory problems, in Subramanian G, Rhodes BA, Cooper J, et al (eds): Radiopharmaceuticals. New York, NY, Society of Nuclear Medicine, 1975, pp 259-263en_US
dc.identifier.citedreferenceFood and Drug Administration: Radioactive new drugs for investigational use. Fed Reg 28:183, January 8, 1963en_US
dc.identifier.citedreferenceFood and Drug Administration: Radioactive new drugs: New-drug application requirements. Fed Reg 36: 21026, November 3, 1971en_US
dc.identifier.citedreferenceHalperin JA, Stringer SA, Eastep RD: Regulation of radiopharmaceuticals: Analysis of radiopharmaceuticals approved for marketing in the United States 1951-1978, in: Radiopharmaceuticals II, Proceedings of the Second International Symposium on Radiopharmaceuticals. New York, NY, Society of Nuclear Medicine, 1979, p xxien_US
dc.identifier.citedreferenceFood and Drug Administration: Radioactive new drugs and radioactive biologics. Termination of exemptions. Fed Reg 40:31298, July 25, 1975en_US
dc.identifier.citedreferenceVandergrift, JF: Regulatory problems in nuclear medicine, in Hladik WB, Saha GB, Study KT (eds): Essentials of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 321-330en_US
dc.identifier.citedreferenceKowalsky RJ, Perry JR: Licensing, regulatory control and radiation safety, in: Radiopharmaceuticals in Nuclear Medicine Practice. Norwalk, CT, Appleton & Lange, 1987, pp 473-500en_US
dc.identifier.citedreferenceChilton HM, Witcofski RL: Regulations affecting radiopharmaceuticals, in: Nuclear Pharmacy: An Introduction to the Clinical Application of Radiopharmaceuticals. Philadelphia, PA, Lea & Febiger, 1986, pp 150-157en_US
dc.identifier.citedreferenceNuclear Regulatory Commission: Regulation of medical uses of radioisotopes. Statement of general policy. Fed Reg 44:8242, February 9, 1979en_US
dc.identifier.citedreferenceGuide for the preparation of applications for medical use programs: Regulatory Guide 10.8 (Task FC 415-4), Revision 2. Washington, DC, Nuclear Regulatory Commission, August 1987en_US
dc.identifier.citedreferenceFink JL, Marquardt KW, Simonsmeier IM (eds): Pharmacy Law Digest, Facts and Comparisons. Philadelphia, PA, Lippincott, 1987, pp DC-19en_US
dc.identifier.citedreferenceLevine G., Massetti C., Malhi B.: A methodology for preparing pediatric doses of 99m Tc MAA for pulmonary perfusion studies. J Nucl Med Technol 8:94-96, 1980en_US
dc.identifier.citedreferenceSiegel BA: Radiopharmaceuticals and FDA: A clinician's perspective. J Nucl Med Technol 11:177-186,1983en_US
dc.identifier.citedreferenceNuclear Pharmacy Guideline: Criteria for determining when to register as a drug establishment, Division of Drug Labeling and Compliance (HFN-310). Washington, DC, Center for Drugs and Biologics, Food & Drug Administration, May 1984en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10.1177_089719008900200509.pdf
Size:
671.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.